Veteran affairs diabetes trial vadt

In addition, a dose-response relationship was found between serious hypoglycemia and CAC progression in the standard therapy group only. Despite a higher frequency of serious hypoglycemia in the intensive therapy group, serious hypoglycemia was associated with progression of CAC in only the standard therapy group. Sign In or Create an Account. Advanced Search. User Tools. Sign In. Skip Nav Destination Article Navigation.

Close mobile search navigation Article navigation. Volume 39, Issue 3. Previous Article Next Article. Article Navigation. Cardiovascular and Metabolic Risk January 19 Intensive glucose control reduces development of nephropathy and retinopathy but not neuropathy, though evaluations of neuropathy are less consistent and conclusions regarding outcomes less reliable.

Of interest, the 5-year post trial period included 3 additional years of HbA1c separation between treatment groups which suggests that longer-term glucose control may be needed before benefits are seen. Article Navigation. Cardiovascular and Metabolic Risk June 29 Nasrin Azad. Corresponding author: Nasrin Azad, nasrin. This Site. Google Scholar. Lily Agrawal ; Lily Agrawal.

Gideon Bahn ; Gideon Bahn. Nicholas V. Emanuele ; Nicholas V. Peter D. Reaven ; Peter D. Rodney Hayward ; Rodney Hayward. Bahn va.

More Information Study ClinicalTrials. Dimensions for VA is a database that connects publications, grants, patents, clinical trials, and policy documents. To determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 diabetes mellitus who are no longer responsive to oral agents alone To evaluate the effects on microangiopathy, quality of life, and cost effectiveness.

Demographic characteristics Clinical characteristics such as time since diabetes mellitus diagnosis, concomitant medications, weight, body mass index, blood pressure, cholesterol, smoking status Occurrence of study primary endpoints: acute myocardial infarction, death from cardiovascular disease, stroke, congestive, heart failure, amputation from peripheral vascular disease PVD , surgical intervention for coronary or PVD, and critical limb ischemia Occurrence of study secondary endpoints: angina, claudication, retinopathy, nephropathy, neuropathy, quality of life, cognitive function, and cost-effectiveness.

Medical records Clinical visits. Study ClinicalTrials.